Molecular Targeting Probes - Radioactive & Nonradioactive -> Radiopharmacy 470

470 - Radiosynthesis of [18F]-flumazenil and its clinical utilization. (ID 341)

Session Name
Radiopharmacy
Speakers
Authors
Presentation Topic
Molecular Targeting Probes - Radioactive & Nonradioactive -> Radiopharmacy
Presentation Number
470

Previous Eposter
469 - Improved synthesis of [18F]fluoro-d2-methyl tosylate suitable for automated pharmaceutical labeling (ID 342)

Next Eposters
471 - Synthesis and preclinical evaluation of a molecular probe for imaging lung cancer with L858R/T790M mutation of epidermal growth factor receptor (EGFR) (ID 340)
472 - Histopathologic correlation with 68Ga PSMA PET/CT in Non Prostate Tumors. (ID 522)
473 - Clinical Application of SPECT-CT Imaging with 99mTc/PSMA T4 in patients with Recurrent Prostate Cancer (ID 523)
474 - A Pilot Study on 68Ga-PSMA-11 PET/CT in Assessing Metastatic Clear Cell Renal Cell Carcinoma (ID 521)
475 - 68Ga-PSMA PET/MRI for the Diagnoses of Primary and Biochemical Recurrent Prostate Cancer: A System Review and Meta-Analysis (ID 520)
477 - [18F]DCFPyL associated radioactivity in patient saliva samples. (ID 527)
484 - Imaging characteristics and diagnostic performance of 18F-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy (ID 547)
486 - 18F-FDG PET/CT in prognostication of malignant peripheral nerve sheath tumors. (ID 551)
487 - Prognostic and predictive interest of 18F-FDG PET/CT in the initial assessment of stage III B-C-D and IV patients with melanoma before anti-PD-1 immunotherapy. (ID 545)
489 - Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy (ID 546)